About Helio Vision
Helio Vision is a Healthcare company based in Waltham (United States) founded in 2016, and was acquired by Aldeyra in January 2019. Developer of small molecule based therapeutics for the treatment of eye diseases. Helio Vision has raised $1.77 million across 3 funding rounds from investors including Aldeyra. Its focus areas include Life Sciences, Ophthalmology, Drugs and Diversified. Its competitors include Annexon, Aldeyra and Gyroscope; 2 of its 3 listed competitors have raised funding.
Company details
Helio Vision was established in 2016 and is based in Waltham, United States. Small molecule-based therapeutics targeting eye diseases, with a primary focus on proliferative vitreoretinopathy, are being advanced by the company within the biotechnology sector. The lead product candidate, ADX-2191, has been progressed through Phase 2 clinical trials for treatment applications. Operations center on therapeutic development for ocular conditions.
- Headquarters Waltham, United States
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Website heliovisioninc.com
- Acquired by Aldeyra (Jan 2019)
Funding Insights of Helio Vision
Helio Vision has successfully raised a total of $1.77M across 3 strategic funding rounds. The most recent funding activity was a Seed round of $1.02 million completed in June 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $1.77M
- Total Rounds 3
- Last Round Seed — $1.02M
- First Round $259,504
(Aug 2016)
All 3 funding rounds of Helio Vision with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2018 | $1.02M | Seed | – | – | – |
| Dec 2017 | $500,000 | Seed | – | – | – |
| Aug 2016 | $259,504 | Seed | – | – | – |
1 investors in total: 1 institutional.
Investors in Helio Vision
Helio Vision has secured backing from 1 investor. Prominent investors backing the company include Aldeyra.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Drug candidates for immune-mediated diseases are developed by Aldeyra. | 2004 | aldeyra.com | Lexington, United States |
Investor details for Helio Vision
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Helio Vision
4 dated milestones of Helio Vision across 3 years, from founding to its latest funding, stage changes and deals.
- Founded Helio Vision is founded.
- Funding First funding round of $260K.
- Funding Latest funding round, Seed, of $1.0M.
- Exit Acquired by Aldeyra.
Competitors of Helio Vision
Helio Vision has 3 listed competitors in our database, 2 of them funded. They include Annexon, Aldeyra and Gyroscope.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| annexonbio.com | 2011 | San Francisco, United States | $256M | 80 | Developer of antibodies to treat complement-mediated neurodegenerative diseases | |
| aldeyra.com | 2004 | Lexington, United States | $4.79M | 30 | Drug candidates for immune-mediated diseases are developed by Aldeyra. | |
| gyroscope.cc | 2016 | San Francisco, United States | Mobile SDK developed for app engagement and monetization strategies. |
Detailed competitors of Helio Vision
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Ophthalmology
3 companies that operate in the same segment as Helio Vision (Ophthalmology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of a wide range of eye care products | 1945 | Fort Worth, Texas, United States | USD 171.61 M | USD 9.64 B | 25,600 | |
Genetic medicines are developed by 4DMT for transformative therapies. | 2013 | Emeryville, California, United States | USD 186.59 M | USD 85.21 M | 227 | |
Developer of antibodies to treat complement-mediated neurodegenerative diseases | 2011 | San Francisco, California, United States | USD 256 M | 100 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Helio Vision
Complete news archive for Helio Vision
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Helio Vision
Helio Vision was founded in 2016.
Helio Vision is headquartered in Waltham, United States. It is registered at Waltham, Massachusetts, United States.
Helio Vision is a funded company, having raised a total of $1.77M across 3 funding rounds to date. The company's 1st funding round was a Seed of $259.5K, raised on Aug 2016.
Helio Vision was established in 2016 and is based in Waltham, United States. Small molecule-based therapeutics targeting eye diseases, with a primary focus on proliferative vitreoretinopathy, are being advanced by the company within the biotechnology sector. The lead product candidate, ADX-2191, has been progressed through Phase 2 clinical trials for treatment applications. Operations center on therapeutic development for ocular conditions.
Helio Vision has 1 investor. Key investors include Aldeyra.
Yes. Helio Vision was acquired by Aldeyra in January 2019.